• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Wellbutrin Augmentation: When Does It Work?

Wellbutrin Augmentation: When Does It Work?

January 1, 2019
Chris Aiken, MD
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Chris Aiken, MD Editor-in-Chief of The Carlat Psychiatry Report. Practicing psychiatrist, Winston-Salem, NC. Dr. Aiken has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Each month, Editor-in-Chief Chris Aiken, MD, gives advice on a different practice challenge.

Dear Dr. Aiken: In the July/August 2018 issue, you wrote that ­bupropion (Wellbutrin) augmentation does not work in ­treatment-resistant depression (TRD). So why do we see it work so often in practice?

Dr. Aiken: When all of the studies are averaged together, bupropion augmentation does not seem to work, but it’s possible that something is lost in the averaging. What if there were two types of depressed patients—some who got worse with bupropion augmentation and others who got better? When lumped together, they would cancel out and give the impression that bupropion makes no difference. That’s what a new analysis of the large CO-MED trial suggests. This study randomized 665 depressed patients into three treatment arms:

  1. Escitalopram + placebo

  2. Escitalopram + bupropion

  3. Venlafaxine + mirtazapine


Outcomes were similar for all three groups after 12 weeks and again after 7 months. That’s not a surprise, as our July/August issue suggested that none of those augmentation strategies perform much better than placebo. However, a different story ­emerges when the patients in that study are stratified by weight or inflammation. Compared to SSRI monotherapy, adding bupropion actually worsened outcomes when patients had a BMI ≤ 25 or low levels of C-reactive protein (CRP < 1 mg/L), a marker for inflammation. When CRP was ≥ 1 mg/L or BMI was ≥ 35, bupropion augmentation performed much better than SSRI monotherapy (remission rates were 1.75 times greater). For mild-moderate obesity (BMI 26–34), the three treatments did not differ (Jha MK et al, J Affect Disord 2018;234:34–37; Jha MK et al, Psychoneuroendo 2017;78:105–113).

These results need replication, but they did not come out of nowhere. Obesity is an inflammatory state, so it makes sense that BMI and CRP predicted similar outcomes. Bupropion is dopaminergic and noradrenergic, and has anti-inflammatory effects. Other research suggests that dopaminergic and noradrenergic antidepressants perform better in inflammatory states than the SSRIs.

Bottom line
Bupropion augmentation is not well-supported by the data, but if you use it, patients with obesity or inflammation may have the best outcomes. If combining bupropion with an SSRI, choose escitalopram or citalopram, as the others can alter its metabolism (see TCPR, Nov/Dec 2018). As for CRP, there’s growing evidence that this biomarker can predict medication response, so look for an update in a future issue.
General Psychiatry
KEYWORDS depression treatment-resistant-depression wellbutrin
    Aiken eic 150x150
    Chris Aiken, MD

    Ketamine Assisted Therapy Part I

    More from this author
    www.thecarlatreport.com
    Issue Date: January 1, 2019
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Deprescribing, TCPR, January 2019
    Brexanolone: A New Treatment for Postpartum Depression
    Is Ketamine Just Another Opiate?
    Cannabidiol for Schizophrenia
    Wellbutrin Augmentation: When Does It Work?
    Deprescribing Medication
    Prescription CBD Is Available, But Are We Ready to Use It?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.